Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 16,249 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Double-blind placebo Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

NCT05268016
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ME3183, Placebo
Drug
Lead sponsor
Meiji Pharma USA Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 30, 2026, 10:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04532749
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 30, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

NCT04680026
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
HBI-3000, Placebo
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Naples, Florida • Springfield, Illinois • Tupelo, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 30, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

NCT03923478
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Interventions
ABI-M201, Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Oakland, California • San Carlos, California • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

NCT00724815
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101 - Sumatriptan iontophoretic transdermal patch, Placebo
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 30, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 30, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

NCT01769417
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Placebo, MEDI4893
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 30, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

Bumetanide in Patients With Alzheimer's Disease

NCT06052163
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bumetanide, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD3293 Thorough QT Study in Healthy Male Volunteers

NCT02040987
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AZD3293, Placebo, Moxifloxacin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

NCT00813293
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib, radiofrequency ablation
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis

NCT00426621
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Diclofenac Sodium Gel, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
35 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
64
States / cities
Mobile, Alabama • Tallassee, Alabama • Chandler, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2007 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

NCT01154621
View directory record Official record
Conditions
Tolerability, Healthy, Elderly
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

NCT01876784
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Vandetanib (SAR390530), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Torrance, California • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

NCT00287547
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
CTLA4Ig / Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
10
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1607 SAD Study in Healthy Subjects

NCT01791049
View directory record Official record
Conditions
Serious Infections Due to Known or Suspected Gram-positive Pathogens
Interventions
TD-1607, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults

NCT00480155
View directory record Official record
Conditions
Healthy
Interventions
Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

NCT00656578
View directory record Official record
Conditions
Pain
Interventions
4975, Placebo
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Bakersfield, California • Owings Mills, Maryland • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers

NCT02236026
View directory record Official record
Conditions
Healthy
Interventions
Supratherapuetic dose of Nestorone, Placebo, Moxifloxacin
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

NCT00453999
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 200 mg, Peramivir 400 mg, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Sep 30, 2026, 10:03 AM EDT
Not listed Phase 3 Interventional

NB-001 Treatment of Recurrent Herpes Labialis

NCT01695187
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001 (0.3%), Placebo
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

NCT00548587
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Beloit, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

NCT01904604
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 30, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 30, 2026, 10:03 AM EDT